Humanized Anti-CD6 mAb for Treating of Autoimmune Diseases


Feng Lin, PhD


Contact Innovation Manager

Jason Ospina, PhD

What is it? What does it do?

Dr. Lin’s research suggests that targeting CD6 gene is a promising effective treatment for Multiple Sclerosis. He has demonstrated: (1) CD6-deficient mice were protected from central nervous injury in experimental autoimmune encephalomyelitis (EAE); (2) CD6 mice show reduced pathogenic T cell responses, indicating that CD6 is a positive regulator of T cell activation which plays an important role in pathogenesis of MS; (3) Systemic administration of our humanized anti-CD6 antibody reversed EAE disease progression in CD6 humanized mice, further supporting the hypothesis that our approach could be effective in treating Multiple Sclerosis.

Why is it better?

  • The antibody has been humanized
  • It has been demonstrated in a humanized EAE Model
  • The specific target may have applications to a range of immunological diseases

What is its current status?

To develop a potential anti-CD6 mAb therapeutic from the precursor molecule which showed great efficacy in treating animal models of MS, Dr. Lin is currently working on the humanization process to minimize its antigenicity. He will compare the treatment efficacies of the lead humanized mAb (based on their binding affinities) then pick the most effective one for further studies.

IP Status





Other Technologies by Inventor

Other Technologies by Innovation Manager

Get in Touch With Us